Status Epilepticus Market: By Type (Conclusive and Non-Conclusive Epilepticus), By Drug (Ganaxolone, Diazepam, Phenobarbital, Phenytoin and Fosphenytoin, Valproate, and Others), By Distribution Channel (Retail Pharmacy, Online Pharmacy, and Hospital Pharmacy), and Geography

Status Epilepticus Market was valued at USD 1,236 million in 2022 and is poised to reach USD 5,426 million by 2029, growing at a 6.5% CAGR from 2023 to 2029. According to the National Institutes of Health, Status epilepticus is defined as a seizure with 5 minutes or more of continuous clinical and/or electrographic seizure activity or recurrent seizure activity without recovery between seizures. Status epilepticus treatment is addressed rapidly and in an organized manner with simultaneous management of the breathing, circulation, and airway while administering antiepileptic drug treatment. The primary objective is to abort the seizure as rapidly as possible with no harm to the patient to their cardiovascular systems. Drugs included for treatment are ganaxolone, diazepam, phenobarbital, phenytoin Fosphenytoin, and others. The high prevalence of the neurological disorder among men is expected to increase in demand for status epilepticus market, the epidemiology of epilepticus shows a higher risk of epilepsy in men as compared to women.

According to the World Health Organization (WHO), Status epilepticus is a chronic, noncommunicable disease that affects more than 55 million people across the world. This factor drives the status epilepticus market. With the increasing prevalence of neurological disorders government is providing funding for research and development activities, enhancing clinical trials for such drugs, and raising drug approval by authorized organizations to lower the risk for epilepsy disorder in the market which leads to creating new opportunities in the market. With the amplified cost of expenditure for the treatment several key players spending a lot in research and development for the treatment, and in return the cost has increased, a greater number of economic people are unable to proceed due to high treatment costs which is the major restraints in status epilepticus market. Geographically, North America held the major market share in 2022 and is expected to dominate the status epilepticus market due to the presence of several key players in the region.

Status Epilepticus Market Key Developments:

In March 2022, Marinus Pharmaceuticals Announces FDA Approval of ZTALMY® (ganaxolone) for CDKL5 Deficiency Disorder. ZTALMY® (ganaxolone) is an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder (CDD), a rare form of genetic epilepsy, in patients two years of age and older, ZTALMY® is a neuroactive steroid that acts as a positive allosteric modulator of the GABAA receptor.